{"id":2093,"date":"2024-06-24T17:16:20","date_gmt":"2024-06-24T17:16:20","guid":{"rendered":"https:\/\/healthmedicinet.com\/review\/fda-approves-keytruda-plus-chemo-for-primary-advanced-recurrent-endometrial-carcinoma\/"},"modified":"2024-06-24T17:16:20","modified_gmt":"2024-06-24T17:16:20","slug":"fda-approves-keytruda-plus-chemo-for-primary-advanced-recurrent-endometrial-carcinoma","status":"publish","type":"post","link":"https:\/\/healthmedicinet.com\/review\/fda-approves-keytruda-plus-chemo-for-primary-advanced-recurrent-endometrial-carcinoma\/","title":{"rendered":"FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma"},"content":{"rendered":"<p>The U.S. Food and Drug Administration has approved Merck&#8217;s Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved indication for Keytruda in endometrial carcinoma. The approval is for Keytruda, an anti-programmed death receptor-1 (anti-PD-1) therapy, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The FDA based its approval on data from the Phase III KEYNOTE-868 trial, in which Keytruda plus <a class=\"read-more-link\" href=\"https:\/\/healthmedicinet.com\/fda-approves-keytruda-plus-chemo-for-primary-advanced-recurrent-endometrial-carcinoma\/\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration has approved Merck&#8217;s Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved indication for Keytruda in endometrial carcinoma. The approval is for Keytruda, an anti-programmed death receptor-1 (anti-PD-1) therapy, in combination with carboplatin and paclitaxel, followed by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2093","post","type-post","status-publish","format-standard","hentry","category-health-news"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts\/2093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/comments?post=2093"}],"version-history":[{"count":0,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts\/2093\/revisions"}],"wp:attachment":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/media?parent=2093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/categories?post=2093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/tags?post=2093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}